Testing targeted drugs plus chemo for newly diagnosed AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study compares standard chemotherapy to chemotherapy plus CPX-351 and/or gilteritinib in children and young adults newly diagnosed with AML. It aims to see whether adding these targeted treatments improves outcomes, especially for certain gene changes like FLT3.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be under 22 years old when starting the study.
- You have a new diagnosis of de novo AML (not AML from another blood problem).
- Your AML test results must meet one of the study’s blast or genetic criteria from a recent sample (about the last 14 days).
- To join certain treatment groups, your tumor type may need specific FLT3 gene changes, and a specific ratio threshold for FLT3/ITD.
- If you join the gilteritinib groups, you (and your caregiver) must agree to reliable birth control rules and not breastfeed during the required time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This study tests a new way to monitor and treat AML in children and young adults after their first chemotherapy. It aims to improve outcomes by closely tracking the disease and adjusting treatment as needed.
This study tests whether CPX-351 can work better than standard intensive chemotherapy in adults with newly diagnosed AML that fits specific genetic patterns. It aims to improve how long patients stay in control of the leukemia.
This Phase 1 trial tests a new combination of CPX-351 plus gemtuzumab ozogamicin for people newly diagnosed with acute myeloid leukemia (AML). It aims to find a safe dose and see how well the treatment works, especially when the leukemia cells carry a target called CD33.
This early-phase study tests a menin inhibitor drug (SNDX-5613) combined with standard induction chemotherapy (daunorubicin plus cytarabine) in newly diagnosed AML with specific gene changes (NPM1 or FLT3 status, or MLL/KMT2A or NUP98). It may help patients whose AML has these genetic features respond better to intensive treatment.
This trial tests a new combination of two drugs (bortezomib and CPX-351) for people newly diagnosed with a specific type of AML that has a TP53 gene change. The goal is to see if this combination is safe and works better than standard treatment.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.